NKTR Nektar Therapeutics

NASDAQ
$57.06

Nektar Therapeutics (NKTR) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal Bearish Selling ran elevated versus NKTR's own trailing one-year pace, with 96% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 2 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
2
10 transactions
Purchases
$0
0 shares
Sales
$2.0M
32,466 shares
Net activity
-$2.0M
purchases less sales

How much of that selling was preplanned? 96% planned / 4% discretionary

10b5-1 plan sales $1.9M 6 transactions · 31,219 shares
Discretionary sales $85.6K 4 transactions · 1,247 shares

Largest single sale: $397.7K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
ROBIN HOWARD W President & CEO Sell 418 $71.98 $30.1K 54,627 −0.8% of holding
Zalevsky Jonathan Chief R&D Officer Sell 186 $71.98 $13.4K 9,570 −1.9% of holding
Zalevsky Jonathan Chief R&D Officer Sell 10b5-1 5,681 $70.00 $397.7K 9,756 −36.8% of holding
ROBIN HOWARD W 2 fills President & CEO Sell 10b5-1 10,000 $61.19 $611.9K 59,545 −14.4% of holding
ROBIN HOWARD W 2 fills President & CEO Sell 10b5-1 10,000 $60.32 $603.2K 69,742 −12.5% of holding
Zalevsky Jonathan Chief R&D Officer Sell 10b5-1 5,538 $60.71 $336.2K 15,437 −26.4% of holding
ROBIN HOWARD W President & CEO Sell 444 $65.51 $29.1K 75,045 −0.6% of holding
Zalevsky Jonathan Chief R&D Officer Sell 199 $65.51 $13.0K 20,975 −0.9% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.